Pfizer's Xeljanz elected in US as 1st JAK in RA

The US FDA on 6 November sanctioned pharma giant Pfizer's Xeljanz (tofacitinib citrate) as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or are intolerant to methotrexate – granting the approval two weeks ahead of the medicine's action goal date.

The drug is the first Janus kinase (JAK) inhibitor approved for RA – only the second JAK inhibitor to gain...